Clinical Trial Update: Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an immunomodulator as adjunct therapy for retreatment pulmonary tuberculosis has completed, reporting its efficacy and safety finding…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Immunomodulator (immunomodulator)

Snippet

Sponsor: Ministry of Science and Technology, India | Conditions: Tuberculosis | Phase 3 | Status: COMPLETED